O	0	5	SPECT
O	6	14	analysis
O	15	17	of
O	18	25	cardiac
O	26	35	perfusion
O	36	43	changes
O	44	49	after
O	50	55	whole
O	55	56	-
O	56	62	breast
O	62	63	/
O	63	68	chest
O	69	73	wall
O	74	83	radiation
O	84	91	therapy
O	92	96	with
O	97	99	or
O	100	107	without
B-intervention	108	114	active
I-intervention	115	124	breathing
I-intervention	125	136	coordinator
O	136	137	:
O	138	145	results
O	146	148	of
O	149	150	a
O	151	161	randomized
O	162	167	phase
O	168	169	3
O	170	175	trial
O	175	176	.

O	177	184	Cardiac
O	185	191	muscle
O	192	201	perfusion
O	201	202	,
O	203	205	as
O	206	216	determined
O	217	219	by
O	220	226	single
O	226	227	-
O	227	233	photon
O	234	242	emission
O	243	251	computed
O	252	262	tomography
O	263	264	(
O	264	269	SPECT
O	269	270	)
O	270	271	,
O	272	281	decreases
O	282	287	after
O	288	294	breast
O	295	298	and
O	298	299	/
O	299	301	or
O	302	307	chest
O	308	312	wall
O	313	314	(
O	314	317	BCW
O	317	318	)
O	319	330	irradiation
O	330	331	.

O	332	335	The
O	336	342	active
O	343	352	breathing
O	353	364	coordinator
O	365	366	(
O	366	369	ABC
O	369	370	)
O	371	378	enables
O	379	388	radiation
O	389	397	delivery
O	398	402	when
O	403	406	the
O	407	410	BCW
O	411	413	is
O	414	421	farther
O	422	426	from
O	427	430	the
O	431	436	heart
O	436	437	,
O	438	445	thereby
O	446	456	decreasing
O	457	464	cardiac
O	465	473	exposure
O	473	474	.

O	475	477	We
O	478	490	hypothesized
O	491	495	that
O	496	499	ABC
O	500	505	would
O	506	513	prevent
B-condition	514	523	radiation
I-condition	523	524	-
I-condition	524	531	induced
I-condition	532	539	cardiac
I-condition	540	548	toxicity
O	549	552	and
O	553	562	conducted
O	563	564	a
O	565	575	randomized
O	576	586	controlled
O	587	592	trial
O	593	603	evaluating
O	604	614	myocardial
O	615	624	perfusion
O	625	632	changes
O	633	638	after
O	639	648	radiation
O	649	652	for
O	653	657	left
O	657	658	-
O	658	663	sided
O	664	670	breast
O	671	677	cancer
O	678	682	with
O	683	685	or
O	686	693	without
O	694	697	ABC
O	697	698	.

B-eligibility	699	705	Stages
I-eligibility	706	707	I
I-eligibility	708	710	to
I-eligibility	711	714	III
I-eligibility	715	719	left
I-eligibility	720	726	breast
I-eligibility	727	733	cancer
I-eligibility	734	742	patients
I-eligibility	743	752	requiring
I-eligibility	753	761	adjuvant
I-eligibility	762	771	radiation
I-eligibility	772	779	therapy
I-eligibility	780	781	(
I-eligibility	781	784	XRT
I-eligibility	784	785	)
O	786	790	were
O	791	801	randomized
O	802	804	to
O	805	808	ABC
O	809	811	or
B-control	812	814	No
I-control	814	815	-
I-control	815	818	ABC
O	818	819	.

O	820	830	Myocardial
O	831	840	perfusion
O	841	844	was
O	845	854	evaluated
O	855	857	by
O	858	863	SPECT
O	864	869	scans
O	870	871	(
O	871	877	before
O	878	881	and
O	882	883	6
O	884	890	months
O	891	896	after
O	897	900	BCW
O	901	910	radiation
O	910	911	)
O	912	917	using
O	918	919	2
O	920	927	methods
O	927	928	:
O	929	930	(
O	930	931	1
O	931	932	)
O	933	938	fully
O	939	948	automated
O	949	961	quantitative
O	962	967	polar
O	968	975	mapping
O	975	976	;
O	977	980	and
O	981	982	(
O	982	983	2
O	983	984	)
O	985	1001	semiquantitative
O	1002	1008	visual
O	1009	1019	assessment
O	1019	1020	.

O	1021	1024	The
O	1025	1029	left
O	1030	1039	ventricle
O	1040	1043	was
O	1044	1051	divided
O	1052	1056	into
O	1057	1059	20
O	1060	1068	segments
O	1069	1072	for
O	1073	1076	the
O	1077	1082	polar
O	1083	1086	map
O	1087	1090	and
O	1091	1093	17
O	1094	1102	segments
O	1103	1106	for
O	1107	1110	the
O	1111	1117	visual
O	1118	1124	method
O	1124	1125	.

O	1126	1134	Segments
O	1135	1139	were
O	1140	1147	grouped
O	1148	1150	by
O	1151	1161	anatomical
O	1162	1167	rings
O	1168	1169	(
O	1169	1175	apical
O	1175	1176	,
O	1177	1180	mid
O	1180	1181	,
O	1182	1187	basal
O	1187	1188	)
O	1189	1191	or
O	1192	1194	by
O	1195	1203	coronary
O	1204	1210	artery
O	1211	1223	distribution
O	1223	1224	.

O	1225	1228	For
O	1229	1232	the
O	1233	1239	visual
O	1240	1246	method
O	1246	1247	,
O	1248	1249	2
O	1250	1257	nuclear
O	1258	1266	medicine
O	1267	1277	physicians
O	1277	1278	,
O	1279	1286	blinded
O	1287	1289	to
O	1290	1299	treatment
O	1300	1306	groups
O	1306	1307	,
O	1308	1314	scored
O	1315	1319	each
O	1320	1327	segment
O	1327	1328	'
O	1328	1329	s
O	1330	1339	perfusion
O	1339	1340	.

O	1341	1347	Scores
O	1348	1352	were
O	1353	1361	analyzed
O	1362	1366	with
O	1367	1380	nonparametric
O	1381	1386	tests
O	1387	1390	and
O	1391	1397	linear
O	1398	1408	regression
O	1408	1409	.

O	1410	1417	Between
O	1418	1422	2006
O	1423	1426	and
O	1427	1431	2010
O	1431	1432	,
B-total-participants	1433	1435	57
O	1436	1444	patients
O	1445	1449	were
O	1450	1458	enrolled
O	1459	1462	and
B-total-participants	1463	1465	43
O	1466	1470	were
O	1471	1480	available
O	1481	1484	for
O	1485	1493	analysis
O	1493	1494	.

O	1495	1498	The
O	1499	1506	cohorts
O	1507	1511	were
O	1512	1516	well
O	1517	1524	matched
O	1524	1525	.

O	1526	1529	The
O	1530	1536	apical
O	1537	1540	and
O	1541	1545	left
O	1546	1554	anterior
O	1555	1565	descending
O	1566	1574	coronary
O	1575	1581	artery
O	1582	1590	segments
O	1591	1594	had
O	1595	1606	significant
O	1607	1616	decreases
O	1617	1619	in
O	1620	1629	perfusion
O	1630	1632	on
O	1633	1638	SPECT
O	1639	1644	scans
O	1645	1647	in
O	1648	1652	both
O	1653	1656	ABC
O	1657	1660	and
O	1661	1663	No
O	1663	1664	-
O	1664	1667	ABC
O	1668	1675	cohorts
O	1675	1676	.

O	1677	1679	In
O	1680	1690	unadjusted
O	1691	1694	and
O	1695	1703	adjusted
O	1704	1712	analyses
O	1712	1713	,
O	1714	1725	controlling
O	1726	1729	for
O	1730	1742	pretreatment
O	1743	1752	perfusion
O	1753	1758	score
O	1758	1759	,
O	1760	1763	age
O	1763	1764	,
O	1765	1768	and
O	1769	1781	chemotherapy
O	1781	1782	,
O	1783	1786	ABC
O	1787	1790	was
O	1791	1794	not
O	1795	1808	significantly
O	1809	1819	associated
O	1820	1824	with
O	1825	1835	prevention
O	1836	1838	of
O	1839	1848	perfusion
O	1849	1857	deficits
O	1857	1858	.

O	1859	1861	In
O	1862	1866	this
O	1867	1877	randomized
O	1878	1888	controlled
O	1889	1894	trial
O	1894	1895	,
O	1896	1899	ABC
O	1900	1904	does
O	1905	1908	not
O	1909	1915	appear
O	1916	1918	to
O	1919	1926	prevent
O	1927	1936	radiation
O	1936	1937	-
O	1937	1944	induced
O	1945	1952	cardiac
O	1953	1962	perfusion
O	1963	1971	deficits
O	1971	1972	.
